Impax Asset Management Group plc Buys 157,809 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Impax Asset Management Group plc grew its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 9.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,793,010 shares of the medical research company's stock after acquiring an additional 157,809 shares during the quarter. IQVIA comprises 1.7% of Impax Asset Management Group plc's investment portfolio, making the stock its 16th largest position. Impax Asset Management Group plc owned about 0.98% of IQVIA worth $423,885,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. QRG Capital Management Inc. raised its position in shares of IQVIA by 2.1% during the 3rd quarter. QRG Capital Management Inc. now owns 6,190 shares of the medical research company's stock valued at $1,467,000 after buying an additional 130 shares in the last quarter. Asset Management One Co. Ltd. raised its position in IQVIA by 1.3% during the third quarter. Asset Management One Co. Ltd. now owns 71,077 shares of the medical research company's stock valued at $16,843,000 after purchasing an additional 888 shares in the last quarter. National Pension Service lifted its stake in IQVIA by 12.7% during the third quarter. National Pension Service now owns 435,067 shares of the medical research company's stock worth $103,098,000 after purchasing an additional 49,130 shares during the last quarter. Intact Investment Management Inc. boosted its holdings in shares of IQVIA by 21.8% in the 3rd quarter. Intact Investment Management Inc. now owns 3,180 shares of the medical research company's stock worth $754,000 after purchasing an additional 570 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. increased its position in shares of IQVIA by 0.6% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 118,394 shares of the medical research company's stock valued at $28,056,000 after purchasing an additional 674 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the business's stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have commented on IQV. Truist Financial reduced their price target on shares of IQVIA from $286.00 to $265.00 and set a "buy" rating on the stock in a research report on Monday. JPMorgan Chase & Co. decreased their target price on shares of IQVIA from $288.00 to $279.00 and set an "overweight" rating on the stock in a research report on Wednesday, October 23rd. Royal Bank of Canada reaffirmed an "outperform" rating and set a $270.00 price objective on shares of IQVIA in a research note on Friday. Evercore ISI dropped their target price on IQVIA from $270.00 to $265.00 and set an "outperform" rating for the company in a report on Tuesday, October 8th. Finally, Jefferies Financial Group cut IQVIA from a "buy" rating to a "hold" rating and decreased their price target for the stock from $266.00 to $242.00 in a research note on Wednesday, July 24th. Four research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $261.56.

IQVIA Stock Up 0.5 %

NYSE IQV traded up $1.03 during mid-day trading on Monday, reaching $210.19. The stock had a trading volume of 2,084,472 shares, compared to its average volume of 1,092,093. IQVIA Holdings Inc. has a 1 year low of $190.20 and a 1 year high of $261.73. The company has a fifty day moving average price of $234.31 and a 200 day moving average price of $229.76. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.85. The stock has a market cap of $38.32 billion, a PE ratio of 27.55, a price-to-earnings-growth ratio of 2.01 and a beta of 1.51.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.